Plasma neuropeptide Y in patients with major depressive disorder

被引：6

作者：

Hashimoto, H ^{[1
]}

Onishi, H ^{[1
]}

Koide, S ^{[1
]}

Kai, T ^{[1
]}

Yamagami, S ^{[1
]}

机构：

[1] OSAKA CITY GEN HOSP, OSAKA, JAPAN

来源：

NEUROSCIENCE LETTERS | 1996年 / 216卷 / 01期

关键词：

neuropeptide Y; major depressive disorder; plasma; high performance liquid chromatography; radioimmunoassay analysis; neuropeptide; depression;

D O I：

暂无

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

It has been suggested that neuropeptide Y (NPY) is involved in the pathophysiology of depression. Plasma peptide-rich fraction from patients with major depressive disorder and control subjects was eluted with high performance liquid chromatography (HPLC), followed by radioimmunoassay of NPY. The screening patterns of the NPY-like immunoreactivity in 50 fractions eluted by HPLC from the plasma peptide-rich fraction were different between the two groups. The values of NPY in the 16 controls and the 14 patients were 427 +/- 38 and 310 +/- 27 fmol/ml plasma (P < 0.05), respectively. These results suggest that impaired metabolism of plasma NPY and the reduced plasma NPY in patients with major depressive disorder could be involved in the pathogenesis or pathophysiology of major depressive disorder.

引用

页码：57 / 60

页数：4

共 50 条

[21] Dental Patients with Major Depressive Disorder
Hexem K.
Ehlers R.
Gluch J.
Collins R.
Current Oral Health Reports, 2014, 1 (3) : 153 - 160
[22] High plasma nesfatin-1 level in patients with major depressive disorder
Ari, Mustafa
Ozturk, Oktay Hasan
Bez, Yasin
Oktar, Suleyman
Erduran, Dudu
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2011, 35 (02): : 497 - 500
[23] Increased Plasma S100 Level in Patients with Major Depressive Disorder
Fang, Yuan
Xiao, Shi-Fu
Zhang, Sheng-Yu
Qiu, Qi
Wang, Tao
Li, Xia
CNS NEUROSCIENCE & THERAPEUTICS, 2016, 22 (03) : 248 - 250
[24] Plasma micro-RNA profiles in patients with major depressive disorder (MDD)
Enatescu, V. R.
Papava, I.
Enatescu, I.
Antonescu, M.
Anghel, A.
Seclaman, E.
Sirbu, I. O.
Romosan, R.
Marian, C.
EUROPEAN PSYCHIATRY, 2016, 33 : S182 - S182
[25] Alterations in Plasma Lipidomic Profiles in Adult Patients with Schizophrenia and Major Depressive Disorder
Wang, Fei
Guo, Lin
Zhang, Ting
Cui, Zhiquan
Wang, Jinke
Zhang, Chi
Xue, Fen
Zhou, Cuihong
Li, Baojuan
Tan, Qingrong
Peng, Zhengwu
MEDICINA-LITHUANIA, 2022, 58 (11):
[26] Plasma neuropeptide Y concentrations in patients on hemodialysis
Akagi, S
Nagake, Y
Sugimoto, T
Nakao, K
Yamasaki, H
Ichikawa, H
Makino, H
NEPHRON, 2002, 92 (02): : 333 - 338
[27] Neuropeptide Y and Calcitonin Gene-Related Peptide in Cerebrospinal Fluid in Parkinson's Disease with Comorbid Depression versus Patients with Major Depressive Disorder
Svenningsson, Per
Palhagen, Sven
Mathe, Aleksander A.
FRONTIERS IN PSYCHIATRY, 2017, 8
[28] Comparision of depressive symptoms in schizophrenic patients and patients with major depressive disorder
Szafranski, T
SCHIZOPHRENIA RESEARCH, 2003, 60 (01) : 27 - 27
[29] Associations between plasma metabolites and major depressive disorder
Bot, M.
Thesing, C.
Penninx, B.
BIPOLAR DISORDERS, 2016, 18 : 137 - 137
[30] Plasma norepinephrine and prediction of outcome in major depressive disorder
Johnston, TG
Kelly, CB
Stevenson, MR
Cooper, SJ
BIOLOGICAL PSYCHIATRY, 1999, 46 (09) : 1253 - 1258

← 1 2 3 4 5 →